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Background: Neutrophilic asthma and COPD are obstructive airway diseases common in older
age and have a characteristic airway inflammation with neutrophilic bronchitis. The structural
differences between neutrophilic asthma and COPD have not been investigated. The aim of
this study was to examine the airway and parenchymal abnormalities using high resolution
computed tomographic (HRCT) scanning in participants with neutrophilic asthma, COPD and
smoking controls.
Methods: Participants (neutrophilic asthma (nZ 10), COPD (nZ 17) and smoking controls
(nZ 8)) underwent clinical assessment and sputum induction. HRCT of the chest was per-
formed and independently scored by a radiologist blinded to the subject group using a modified
Bhalla scoring system.
Results: Participants were of a similar age and those with COPD had a similar degree of airflow
obstruction to those with neutrophilic asthma. The pattern of radiographic abnormalities
differed between groups. Abnormal bronchial wall thickening was significantly more common
in neutrophilic asthma, compared to COPD or smoking controls. Emphysema was greatest in
the COPD group, and not recorded as a feature of neutrophilic asthma. FEV1% predicted was
negatively associated with bronchial wall thickening and consolidation while KCO% predicted
was negatively associated with the total emphysema score. Bronchiectasis was minimal in
all groups.ve pulmonary disease; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital capacity; HRCT, High
, Inhaled corticosteroids; NA, Neutrophilic asthma; SC, Smoking controls; TCC, Total cell count.
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882 J.L. Simpson et al.Conclusion: The pattern of radiographic lung abnormality in neutrophilic asthma differs signif-
icantly from COPD, and resembles asthma. Neutrophilic asthma is a distinct inflammatory
subtype of asthma with a different pathogenesis to COPD.
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Asthma is an obstructive airway disease characterised by
an abnormal and heterogeneous airway inflammatory
response. In addition to the allergen driven, corticosteroid
sensitive eosinophilic pattern, many patients exhibit
a noneosinophilic form of the disease that is relatively
resistant to inhaled corticosteroid therapy.1e3 Neutrophilic
asthma (NA) is present in about 20e30% of asthmatics and is
characterised by an intense neutrophilic bronchitis and
dysfunction of the innate immune system.4 The conse-
quences of this response may be airway wall remodelling.
Remodelling is well described with eosinophilic airway
inflammation,5 where the changes can be detected by high
resolution computed tomographic (HRCT) scanning and
include bronchial wall thickening, mosaic lung attenuation,
and mucus plugging.6,7 It is unclear if there are structural
airway changes in neutrophilic asthma.
Chronic Obstructive Pulmonary Disease (COPD) is an
obstructive and inflammatory airway disease typically with
increased neutrophils and like NA; it is more common in
older people. COPD is accompanied by well-established
structural pulmonary changes. Typically this is emphy-
sema, but bronchiectasis and bronchial wall thickening
have recently been recognised to occur in COPD.8,9 Since
there are similarities in the demographic profile and
inflammatory response between NA and COPD, it has been
suggested that NA may be a form of COPD. If this was the
case, then there would be similar structural changes in NA
and COPD.
The purpose of this study was to examine pulmonary
airway and parenchymal changes in NA and COPD using
HRCT of the chest. Since smoking can modify the inflam-
matory response, a group of smoking controls without
known airway disease were included for comparison. We
tested the hypothesis that NA was associated with




Participants with NA (nZ 10), COPD (nZ 17) and smokers
without diagnosed airway disease (SC; nZ 8) were
recruited from the Ambulatory Care Service at John Hunter
Hospital and by advertisement (SC). The participants with
NA and COPD had stable symptoms and treatment, and no
exacerbation or treatment changes in the 4 weeks prior to
enrolment in the study. The participants with NA met
American Thoracic Society criteria for asthma diagnosis10
and had current asthma symptoms, airway hyper-
responsiveness to 4.5% saline, and increased sputum
neutrophil counts (>61%).1 The participants with COPD hadincomplete reversibility of airflow obstruction with post-
bronchodilator FEV1< 80% predicted and FEV/VC ratio
<0.7.11 They had no history of asthma and a significant past
smoking history. The smoker controls were current or
exsmokers with no diagnosed respiratory disease, no
treatment and no airflow obstruction. All participants were
stable (no lower respiratory tract infection or exacerbation
of respiratory disease in the previous 4 weeks) at the time
of assessment.
Design
Participants attended for 2 study visits. At the first visit,
written informed consent was obtained followed by clinical
assessment, spirometry, gas diffusion studies, combined
hypertonic saline challenge and sputum induction as well as
a skin allergy test. Participants then attended a second visit
for chest HRCT. The Hunter Area Health Service and The
University of Newcastle Research Ethics Committees
approved this study.
Chest CT
HRCT of the chest was obtained using Cardiac 64 multislice
scanner (Siemens, Germany). Sections of 1 mm thicknesses
were obtained at 10 mm intervals in full inspiration and in
expiration. A high spatial resolution algorithm was used and
images were photographed at appropriate window settings
(lung window: level e700 HU; window 2000 HU). Scans were
scored independently by a thoracic specialist radiologist
(D.G.M.) blinded to the subject group using a modified
Bhalla scoring system as previously described.12 Both
inspiratory and expiratory scans were scored. Each of six
lobes was scored (the lingula was regarded as a separate
lobe) at inspiratory CT scanning, as previously described,13
using a modification of the Bhalla system.14 Air trapping
was evaluated. The presence and extent of bronchiectasis,
on the basis of established CT criteria,15,16 were scored as
follows: grade 0Z no disease; grade 1Z localised bron-
chiectasis affecting one or part of one bronchopulmonary
segment (localised); grade 2Z bronchiectasis in more than
one bronchopulmonary segment (extensive); grade
3Z generalised cystic bronchiectasis. The average severity
of bronchial dilatation was quantified relative to the
adjacent pulmonary arteries as follows: grade 0Z no
bronchiectasis; grade 1Z 100e200% arterial diameter;
grade 2Z 200e300% arterial diameter; grade 3Z>300%
arterial diameter. Bronchial wall thickness was quantified
relative to the adjacent pulmonary arteries as follows:
grade 0Z none; grade 1Z<50% arterial diameter; grade
2Z 50e100% arterial diameter; grade 3Z>100% arterial
diameter. The presence or absence of mucus within the
large airways and (separately) within the centrilobular
bronchioles was recorded.
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Sputum induction combined with bronchial provocation
testing was performed using ultrasonic nebulisation of 4.5%
saline for doubling time periods.17 Normal (0.9%) saline was
used where pre-bronchodilator FEV1 was <1.5 L. The
sputum was selected from saliva and dispersed using
dithiothreitol as described previously.17 The suspension was
filtered, and a total cell count (TCC) of leucocytes and
viability performed. Cytospins were prepared stained
(MayeGrunwald Geimsa) and a differential cell count
obtained from 400 non-squamous cells. An adequate
sputum sample was one that returned a cell count from
more than 400 non-squamous cells, and a viability of more
than 40%. Determination of IL-8 was by ELISA (R&D Systems,
Minneapolis, MN, USA), previously validated for use in
induced sputum.18
Pulmonary function testing
Participants withheld bronchodilators for their duration of
action before testing. Three reproducible measurements of
FEV1 and FVC were obtained (KoKo PD Instrumentation,
Louisville, CO, USA) before and after inhalation of 200 mg
albuterol via a metered dose inhaler with valved holding
chamber (Volumatic, Allen and Hanbury’s, Melbourne
Victoria, Australia) using predicted values according to
Knudson et al.19 The carbon monoxide transfer co-efficient
(KCO) was determined according to ATS guidelines (Med-
Graphics Elite DX Pulmonary function testing system
Medical Graphics Corporation, Minnesota, MN, USA).20
Data analysis
Data were analysed using Stata 9 (Stata Corporation,
College Station, Texas, USA). Results are reported as
median and interquartile range unless otherwise indicated.
Analysis was performed using the two-sample Wilcoxon
Rank Sum test and Fishers’ exact test for categorical data.Table 1 Clinical and Physiological features of participants wi
disease (COPD) and smoking controls (Controls).
Neutrophilic asthma
N 10
Age, years mean (SD) 65 (10)
Gender, male 5
Atopy, n (%) 9 (90)
Smoker, neverjexjcurent 4j6j0
Pack years median (IQR) 21.5 (0.4e40)#
Duration of airway disease median (IQR) 41.5 (26e47)
FEV1% predicted, mean (SD) 62.1 (22.1)
FEV1: FVC %, mean (SD) 61.2 (11.2)
KCO % predicted, mean (SD) 97.0 (13.5)#
AHR present n (%) 8 (100)
Dose response slope, median (IQR) 2.9 (2.2e12.8)#
ICSa mg/day, median (IQR) 1800 (800e2000)
#p< 0.017 vs. COPD yp< 0.017 vs. NA.
a ICS dose is calculated a 1 mg of beclomethasoneZ 1 mg budesonidAssociations between data were determined using the
Spearman rank correlation. Results were reported as
significant when p< 0.05.
Results
The clinical characteristics of the participants (Table 1)
show that the groups were well matched for age and sex.
There was expected overlap in some phenotypic features,
but each group showed a distinct clinical and physiological
profile. The participants with NA and COPD had a similar
degree of airflow obstruction and inhaled corticosteroid
(ICS) therapy. The participants with NA reported a long
duration of asthma (mean 41 years) and an increased
prevalence of atopy. Gas diffusion (KCO) was normal and all
had airway hyperresponsiveness. In contrast the partici-
pants with COPD had a greater smoking history, reduced
KCO, a lower dose response to hypertonic saline and
a recent diagnosis of airway disease (mean 4 years). The SC
resembled the COPD group in numbers of smokers and
exsmokers, with significantly fewer pack years and a similar
low prevalence of atopy. They had normal FEV1, no diag-
nosed airway disease, no airways hyperresponsiveness and
no ICS use.
The inflammatory markers from induced sputum (Table
2) identified a prominent neutrophilic bronchitis in NA
and COPD. The NA group had the highest values for total
cell count, neutrophil percentage and IL-8, and the COPD
group was intermediate between NA and SC. When
compared to NA and COPD, the SC group had a lower IL-8
level, and an increased proportion of bronchial epithelial
cells.
There were distinct differences in the pattern of HRCT
changes (Table 3). NA had more extensive airway disease,
with increased bronchial wall thickening (Fig. 1) and
minimal emphysema. In contrast, the COPD and SC groups
had significantly less bronchial wall thickening and the
COPD group had more extensive emphysema. None of the
SC group had significant bronchial wall thickening on HRCT.th neutrophilic asthma (NA), chronic obstructive pulmonary
COPD Controls p
17 8
68 (7) 62 (12) 0.214
12 6 0.523
8 (47) 3 (38) 0.039
0j15j2y 0j4j4y 0.001
67.5 (38.8e75) 34.4 (13.0e39.8)# 0.035
4 (2e7) e <0.001
63.8 (16.7) 100.1 (9.9)#,y 0.001
57.6 (8.0) 76.8 (4.7)#,y 0.001
56.5 (16.5) 73.1 (14.8) <0.001
11 (48), nZ 16 0 (0)y# <0.001
1.1 (0.7e2) 0.16 (0.06e0.32)y# <0.001
2000 (2000e2000) nZ 11 e 0.402
eZ 0.5 mg fluticasone.
Table 2 Induced sputum inflammatory markers in neutrophilic asthma (NA), chronic obstructive pulmonary disease (COPD)
and smoking controls (Controls). All data are median (IQR).
Neutrophilic asthma COPD Controls p
Total cell count 106/mL 8.7 (6.6e10.0) 5.1 (3.5e8.6) 3.1 (1.4e5.0)y 0.022
Viability, % 88 (84e93) 90 (77e92) 80 (60e88) 0.223
Neutrophils, % 77.3 (70.1e97.1)# 61.0 (53.5e73.5) 43.3 (20e58.1)y 0.002
Eosinophils, % 1.3 (0.3e2.3) 0.5 (0.3e1.5) 0.3 (0.1e0.4) 0.181
Macrophages, % 19.5 (15.3e24.3) 32.5 (9.5e41.3) 51.9 (33.9e70.9)y 0.008
Lymphocytes, % 0.1 (0.0e0.5) 0.8 (0.3e1.0) 0.8 (0.1e1.6) 0.125
Columnar epithelials, % 0 (0e0.3)# 1 (0.5e2.0) 3.8 (2.0e7.5)y# <0.001
Squamous, % 2.0 (0e3.4) 1.7 (0.5e6.1) 7.0 (1.1e9.6) 0.242
IL-8 ng/mL 41.8 (14.4e75.5) 16.7 (9.9e21.3) 5.1 (2.3e7.3)y# 0.004
#p< 0.017 vs. COPD yp< 0.017 vs. NA.
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There were important correlations observed between
physiological and inflammatory parameters and HRCT
scores. FEV1% predicted was significantly associated with
the degree of bronchial wall thickness, rZ0.443,
pZ 0.008 (Fig. 2) and chest consolidation (rZ0.409,
pZ 0.015) and total lung score (rZ0.454, pZ 0.006). As
expected, KCO% predicted was significantly related to total
emphysema score, rZ0.656, p< 0.001. Induced sputum
neutrophils were significantly associated with a number of
clinical parameters including disease duration (rZ 0.479,
pZ 0.011) and both neutrophils and IL-8 were negatively
associated with the degree of airflow obstruction (FEV/VC,
Neutrophils: rZ0.375, pZ 0.027, IL-8: rZ0.532,
pZ 0.002; and FEV1% predicted, Neutrophils: rZ0.431,
pZ 0.010, IL-8: rZ0.644, p< 0.001). Neutrophils and IL-
8 were also related to bronchial wall thickness (rZ 0.394,
pZ 0.019 and rZ 0.406, pZ 0.024 respectively) but not
with emphysema (rZ0.01, pZ 0.938 and rZ 0.058,
pZ 0.755).
Discussion
This study has demonstrated for the first time that the
pattern of radiographic change from whole lung HRCT
differs between neutrophilic asthma and COPD, further
confirming that neutrophilic asthma represents a distinct
phenotype of inflammatory airway disease. AbnormalTable 3 HRCT changes in neutrophilic asthma, chronic obstructi
Data are median (IQR), or n (%).
Neutrophilic
Bronchial wall thickness score 7 (4e8)
Bronchial walls >50% arterial diameter, n (%) 7 (70)
Mucus plugs present, n (%) 5 (50)
Total emphysema score 0 (0e0)
Extent of bronchiectasis score 0 (0e5)
Severity of bronchiectasis score 0 (0e3)
Decreased attenuation score 15 (10e135)
Number of lobes with decreased attenuation 3 (2e6)
Total lung score 8.5 (4e19)
yp< 0.017 vs. NA.bronchial wall thickness is a well-described CT feature of
asthma and was seen in the neutrophilic asthma group,
where the amount of bronchial wall thickness was signifi-
cantly greater than in the COPD or smoking control groups.
In contrast, emphysema was greatest in the COPD group,
and not recorded as a feature of neutrophilic asthma.
FEV1% predicted was negatively associated with bronchial
wall thickening, while KCO% predicted was negatively
associated with the total emphysema score. Bronchiectasis
was minimal in all groups. These data show that the pattern
of radiographic lung abnormality in neutrophilic asthma is
significantly different from COPD, indicating that neutro-
philic asthma is a distinct inflammatory subtype of asthma
with a different pathogenesis to COPD.
HRCT in asthma
While HRCT has been studied extensively in asthma, the
HRCT changes associated with distinct inflammatory
phenotypes have not been reported previously. The range
of observed abnormalities in asthma includes bronchial wall
thickening, emphysema, bronchiectasis, consolidation,
pneumomediastinum, atelectasis and mosaic lung attenu-
ation.7 In addition, dynamic HRCT shows variability in the
distribution of ventilation,21 treatment responsive changes
in lung attenuation, and altered airway distensibility in
asthma.21e23 More severe forms of asthma are associated
with bronchial wall thickening,24 focal hyperlucency, cen-
trilobular opacity, and bronchiectasis.ve pulmonary disease (COPD) and smoking controls (controls).
asthma COPD Controls p
4 (3e6)y 3.5 (2.5e5)y 0.031
1 (6)y 0 (0)y <0.001
3 (18) 2 (20) 0.211
60 (0e140)y 5 (0e10) 0.004
0 (0e1) 0.5 (0e1) 0.899
0 (0e1) 0.5 (0e1) 0.903
20 (5e30) 7.5 (0e55) 0.443
2 (1e3) 1 (0e5) 0.267
6 (4e7) 4.5 (3e8) 0.214
Figure 1 Bronchial wall thickness score for participants with
neutrophilic asthma, COPD and smoking controls. Horizontal
bar represents the median result. Across group p-value
pZ 0.031. *pZ 0.008 vs. smoking controls #pZ 0.017 vs.
COPD.
Figure 2 Relationship between bronchial wall thickness
score and FEV1% predicted in all participants.
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different subtypes of asthma. In asthma the development
of persistent airflow obstruction was associated with
increased bronchial wall thickening on HRCT.25,26 Bronchial
wall thickening is the most prominent abnormality reported
in asthma. It is considered to be due to submucosal
oedema, inflammation, and airway wall fibrosis, and to be
potentially reversible.27 Inhaled corticosteroid and long-
acting beta-agonist therapy were observed to reduce
bronchial wall thickening28 on HRCT, and these changes
correlated with reduced thickness of the reticular base-
ment membrane and mucosal eosinophils on bronchial
biopsy. Bronchial wall thickening was also related to
increasing asthma severity,24 and is prominent in near fatal
cases of asthma.29 Airway wall thickening is likely to be
a major determinant of airflow obstruction in asthma and
bronchiectasis,29e31 since it correlates with FEV1 in these
conditions.32,33 In this study we also found that the degree
of bronchial wall thickening was significantly correlated
with airflow obstruction.
Changes in an eosinophilic asthma inflammatory
subtype
The HRCT findings in asthma with eosinophilic inflamma-
tion have been compared to nonasthmatic eosino-
philic bronchitis (NAEB).34 The patients with eosinophilic
airway diseases (asthma, NAEB) had a similar pattern of
HRCT changes with increased bronchial wall thickening,
centrilobular prominence and air trapping. Inflammatory
cell activation and airway remodelling were found to be
related to HRCT changes in asthma,35 suggesting that
airway inflammation in asthma is associated with the
extent of airway abnormalities on HRCT, with eosinophilic
inflammation specifically associated with bronchial wall
thickening. Our data extend these findings to show that
neutrophilic inflammation in asthma is also associated
with abnormal bronchial wall thickening. Together these
data suggest that it is the presence, location and possibly
severity of inflammation in asthma that is associated withbronchial wall thickening on HRCT, rather than the
specific inflammatory cell pattern (i.e. eosinophil vs.
neutrophil) that is present. This is further supported by
the data of Wark et al., who studied asthma complicated
by allergic bronchopulmonary aspergillosis where there
is a mixed eosinophil and neutrophil inflammatory
patterns.36 These authors found that both the eosinophil
(ECP) and neutrophil (MPO) activation markers from
induced sputum were correlated with the extent of HRCT
abnormalities.
Bronchial wall thickening in COPD
Inflammatory changes in the small airways due to airway
inflammation have also been identified as an important
pathological abnormality in COPD that is associated with
disease progression.8 A recent HRCT study suggests that
bronchial wall thickening and emphysema have distinct and
separate inheritance patterns in COPD9 and that COPD can
be further subtyped based on the presence of emphysema
and/or bronchial wall thickening.37 Airway wall thickening
is related to the degree of airway obstruction in COPD,38 to
cumulative smoking history and to airway inflammation
with increase in both sputum eosinophils37 and neutro-
phils.39 When HRCT changes in asthma and COPD are
compared25 the parenchymal abnormalities are more
prevalent in COPD, whereas bronchial wall thickening is
more prevalent in asthma compared with COPD. These
results concur with the results of our study where we found
that the extent of bronchial wall thickening was signifi-
cantly greater in neutrophilic asthma than in COPD and
smoking controls, but that parenchymal changes were
greater in COPD. Participants with neutrophilic asthma had
a longer duration of disease compared to participants with
COPD. It would be interesting in further research to inves-
tigate if the degree of bronchial wall thickness is related to
duration of disease.
Other CT changes
Bronchial dilation is another HRCT finding observed in
asthma but is not related to sputum inflammatory markers
or remodelling parameters in asthma.40 In bronchiectasis,
886 J.L. Simpson et al.bronchial dilation did not correlate to the degree of airflow
obstruction, and may possibly protect against airflow
obstruction in bronchiectasis.12 Consequently, it is not
surprising that this HRCT abnormality is not related to
airway inflammation in asthma.
Emphysema and bronchiectasis are uncommon in
asthma. In the present study emphysema was not seen
in the participants with neutrophilic asthma, and when
present, emphysema was associated with smoking, being
present in both COPD and in smoking controls. Emphysema
is now recognised to occur in up to 33% of asymptomatic
smokers,41 consistent with our observations. In COPD, Patel
et al. found evidence of bronchiectasis on HRCT42 which
was associated with increased inflammatory markers,
bacterial colonization and more severe COPD exacerba-
tions. In this study, the extent of bronchiectasis was
minimal in all cases.
Conclusions
This study has demonstrated significant radiological
abnormalities in neutrophilic asthma, the most prominent
of which is bronchial wall thickening. The pattern of
radiographic change in neutrophilic asthma was different
to both COPD and smokers without diagnosed airway
disease. This means that although the neutrophilic
inflammatory pattern may be similar in these airway
conditions, neutrophilic asthma is distinct from COPD in
that it is a dominant airway (and not parenchymal) disease
where there is an intense neutrophilic bronchitis and
probably bronchiolitis. The results support consider-
ation of neutrophilic asthma as a distinct asthma subtype,
which is associated with innate immune dysfunction and
potentially requires identification of different treatment
approaches.
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